查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470918

黑色素瘤治疗药物市场：按类型、产品和分销管道划分 - 全球预测 2024-2030

Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年黑色素瘤治疗市场规模为54亿美元，2024年预估达58.1亿美元，2030年将达94.5亿美元，复合年增长率为8.32%。

黑色素瘤药物是一组专门用于治疗黑色素瘤（一种皮肤癌）的药物。这些药物分为多种类型，包括免疫疗法、标靶治疗、化疗和溶瘤病毒疗法。全球黑色素瘤盛行率的不断上升正在推动治疗药物的创新。此外，政府对医疗保健产业投资的增加和报销政策的扩大正在推动市场成长。然而，与药物开发和治疗相关的高成本正在影响市场成长。严格的监管政策和漫长的核准流程阻碍了持续的研发活动。此外，由于副作用减少和效率高，对标靶治疗的需求不断增长，这为市场成长提供了重要机会。

主要市场统计
基准年[2023] 54亿美元
预测年份 [2024] 58.1亿美元
预测年份 [2030] 94.5亿美元
复合年增长率（%） 8.32%

肢端雀斑样黑色素瘤和恶性雀斑样痣黑色素瘤对非侵入性治疗的需求不断增加

肢端雀斑样黑色素瘤 (ALM) 是黑色素瘤中最不常见的亚型，通常发生在手掌、脚底和指甲下方。对此类药物的需求是由于它们的诊断缓慢且由于缺乏明显的警告信号而难以治疗。恶性雀斑样黑色素瘤 (LMM) 常见于有长期日晒史的老年人。该领域的药物通常关注肿瘤的分子和遗传特征，因为它们往往生长缓慢且浅表。结节性黑色素瘤 (NM) 以其快速、侵袭性生长而闻名，通常在几个月内侵入皮肤深层。最终使用者优先考虑有可能减少结节并改善手术效果的速效治疗方法。表浅扩散性黑色素瘤 (SSM) 是最常见的黑色素瘤类型，通常表现为扩散到皮肤的痣。 SSM 的药物选择通常包括具有预防和长期管理功能的药物，以及可以解决转移的治疗方法。

产品对治疗黑色素瘤疾病进展和基因突变的下一代药物的需求不断增加

黑色素瘤的术后辅助性治疗是指在手术等主要治疗后进行的治疗，以去除残留病灶并降低復发风险。常见的辅助性治疗包括免疫治疗和标靶治疗。化疗将化疗与生物治疗结合起来治疗黑色素瘤患者。当黑色素瘤已经转移且其他治疗方法不够有效时，就需要这种治疗。这是一种更积极的治疗方法，通常在疾病处于晚期时才考虑。Dacarbazine等化疗药物历来被用于治疗转移性黑色素瘤，但这些药物很大程度上已被更新的治疗方法所取代。它主要用于其他治疗方法禁忌或肿瘤不具有可操作突变的情况。免疫治疗药物，例如查核点抑制剂，可以提高免疫系统检测和破坏癌细胞的能力。它通常用于晚期黑色素瘤，包括不可切除或转移性黑色素瘤。溶瘤病毒疗法使用基因工程病毒选择性地感染和破坏癌细胞。对于具有可注射病变和有限扩散的患者，通常首选这种治疗方法。分子标靶治疗作用于与癌症相关的特定分子标靶，对于肿瘤具有可识别基因突变（例如 BRAF V600 突变）的患者来说是首选。这些药物彻底改变了转移性黑色素瘤的治疗模式。

分销管道：由于便利性和远端医疗支持，对线上管道的需求增加

黑色素瘤药物的线下分销管道主要包括医院药房、零售药房和诊所。这些传统管道因其覆盖面广、患者容易获得以及直接获得专业医疗建议和咨询而成为药品分销的支柱。由于技术进步和消费者偏好的变化，黑色素瘤治疗的线上分销管道正在迅速增长。线上药局和药品配送服务在数位平台的支援下为患者提供送货上门的便利，实现处方笺管理、提醒和远端医疗咨询。线下管道可以直接获得专家指导并立即获得药品，这对于急需治疗的患者至关重要。相反，线上管道提供便利、价格实惠，并且能够覆盖更广泛的地理患者群体。

区域洞察

美洲皮肤癌发生率很高，这使其成为黑色素瘤治疗的重要市场。先进的医疗基础设施、对黑色素瘤的高度认识和报销政策促进了强劲的消费者需求。美国黑色素瘤治疗市场受到标靶治疗和免疫治疗创新的推动，并得到 FDA 加速核准有前途的治疗方法的支持。患者援助计划和保险范围通常会影响客户的购买行为。欧洲黑色素瘤药物市场受到严格监管，重点是高效且具成本效益的治疗方法。由于黑色素瘤患者数量的增加和完善的医疗保健系统的存在，欧盟 (EU) 国家表现出很高的消费者需求。新治疗方法的采用受到欧洲药品管理局 (EMA) 和卫生技术评估 (HTA) 机构法规的影响，该机构负责评估新药的价值。黑色素瘤倡议。中东国家对医疗保健的投资不断增加，对创新治疗的需求不断增长。亚太地区黑色素瘤患者的数量正在迅速增加，中国、日本和印度等国家对不断增长的消费需求做出了巨大贡献。在亚太地区，医疗保健和创新投资的增加开始重塑市场。亚太地区黑色素瘤治疗市场受益于政府措施和临床试验中强大的治疗管道的结合。

FPNV定位矩阵

FPNV定位矩阵对于评估黑色素瘤药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对黑色素瘤治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.黑色素瘤治疗药物市场的市场规模和预测是多少？

2.黑色素瘤治疗药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.黑色素瘤治疗药物市场的技术趋势和法规结构是什么？

4.黑色素瘤治疗药物市场主要供应商的市场占有率是多少？

5.进入黑色素瘤药物市场的合适形式和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球黑色素瘤和其他皮肤癌的发生率不断上升
      • 政府增加医疗保健支出
      • 推动肿瘤领域生物相似药的发展
    • 抑制因素
      • 药物开发和治疗成本高昂
    • 机会
      • 对副作用更少、效率更高的标靶治疗的需求不断增加
      • 继续进行旨在推出有效药物的研究和开发活动
    • 任务
      • 严格的监管政策和漫长的核准流程
  • 市场区隔分析
    • 类型：肢端恶性黑色素瘤和恶性雀斑样痣恶性黑色素瘤对非侵入性治疗方法的需求不断增加
    • 产品：对治疗恶性黑色素瘤疾病进展和基因突变的下一代药物的需求增加
    • 分销管道：由于便利和远端医疗支持，对线上管道的需求不断增长
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章黑色素瘤治疗药物市场：依类型

  • 肢端雀斑样黑色素瘤
  • 恶性雀斑
  • 结节性黑色素瘤
  • 表浅黑色素瘤

第七章黑色素瘤治疗药物市场：副产品

  • 辅助性治疗
  • 化疗
  • 化疗药物
  • 免疫治疗药物
  • 溶瘤病毒疗法
  • 标靶治疗

第八章黑色素瘤治疗药物市场：按分销管道

  • 离线
  • 在线的

第九章北美和南美黑色素瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太黑色素瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲黑色素瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Moderna 和默克公司宣布，mRNA-4157 (V940) 和 KEYTRUDA (Pembrolizumab) 的组合将改善高风险 III/IV 期恶性患者的 3 年无復发生存率和免于完全切除的生存率。 ，远处转移存活率。
    • Sun Pharma 和 Philogen 的黑色素瘤治疗在 3 期试验中显示出有希望的结果
    • 美国食品药物管理局核准Opdivo （nivolumab）作为合格的IIB 期或 IIC 期恶性完全切除患者的辅助性治疗
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-0363DFE03682

[194 Pages Report] The Melanoma Drug Market size was estimated at USD 5.40 billion in 2023 and expected to reach USD 5.81 billion in 2024, at a CAGR 8.32% to reach USD 9.45 billion by 2030.

Melanoma drugs are a class of pharmaceutical agents specifically designed to treat melanoma, a type of skin cancer. These drugs can be categorized into various types, including immunotherapies, targeted therapies, chemotherapy, and oncolytic virus therapy. Increasing prevalence of melanoma globally, driving innovations in therapeutics. In addition, growing government investments in the healthcare sector and the expansion of reimbursement policies drive market growth. However, the high costs associated with drug development and treatment impact the market growth. Stringent regulatory policies and lengthy approval processes create hindrances to ongoing research and development activities. Furthermore, emerging need for targeted therapy owing to reduced side effects and higher efficiency poses significant opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 5.40 billion
Estimated Year [2024] USD 5.81 billion
Forecast Year [2030] USD 9.45 billion
CAGR (%) 8.32%

Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma

Acral Lentiginous Melanoma (ALM) is the least common subtype of melanoma, typically occurring on the palms, soles, or under the nails. The need for drugs in this category stems from its late diagnosis and the difficulty in treatment due to the lack of visible warning signs. Lentigo Maligna Melanoma (LMM) is commonly found in elderly patients with a history of chronic sun exposure. The drugs in this segment often focus on the molecular and genetic profiles of tumors since they tend to grow slowly and superficially. Nodular Melanoma (NM) is known for its rapid and aggressive growth, often invading deeper layers of the skin within months. End-users prioritize rapid-acting therapies with the potential to shrink nodules and improve surgical outcomes. Superficial Spreading Melanoma (SSM) is the most common type of melanoma, usually presenting as a spreading mole on the skin. Drug preferences for SSM typically involve medications with preventive and long-term management capabilities alongside treatments that can address metastasis.

Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma

Adjuvant therapy in melanoma refers to treatments given after primary therapies, such as surgery, with the intent to eliminate residual disease and reduce the risk of relapse. Common adjuvant therapies include immunotherapies and targeted therapies. Biochemotherapy combines biological treatment with chemotherapy for melanoma patients. The need for this therapy arises when melanoma has spread and is not responding well to other treatments. It is a more aggressive treatment option and is often considered when the disease is in an advanced stage. Chemotherapy drugs, such as dacarbazine, have historically been used for treating metastatic melanoma but have now largely been replaced by newer therapies. The preference arises primarily when other treatment options are contraindicated or the tumor does not harbor actionable mutations. Immunotherapy drugs, such as checkpoint inhibitors, improve the immune system's ability to detect and destroy cancer cells. Their preference is typically for advanced melanoma, including unresectable and metastatic stages. Oncolytic virus therapy employs genetically modified viruses that selectively infect and destroy cancer cells. Preference for this therapy typically arises for patients with injectable lesions and limited disease spread. Targeted therapy drugs act on specific molecular targets associated with cancer and are preferred for patients with identifiable genetic mutations in their tumors, such as BRAF V600 mutations. These drugs have transformed the treatment landscape for metastatic melanoma.

Distribution Channel: Rising demand of online channel due to convenience and telehealth support

Offline distribution channels for melanoma drugs predominantly include hospital pharmacies, retail pharmacies, and clinics. These traditional channels have been the backbone of pharmaceutical distribution due to their wide reach, patient accessibility, and capability to provide in-person professional medical advice and consultation. The online distribution channel for melanoma drugs is rapidly growing, facilitated by technological advances and changing consumer preferences. Online pharmacies and drug delivery services offer patients the convenience of home delivery, often with the support of digital platforms that allow for prescription management, reminders, and telehealth consultations. Offline channels offer in-person professional guidance and immediate access to medication, which is crucial for patients in urgent need of treatment. Conversely, online channels provide convenience, lower prices, and the ability to reach a wider geographic patient base.

Regional Insights

The Americas have a significant market for melanoma drugs due to a higher incidence of skin cancer. Advanced healthcare infrastructure, high awareness regarding melanoma, and reimbursement policies contribute to robust consumer needs. In the United States, the melanoma drug market is driven by innovation in targeted therapies and immunotherapies, supported by the FDA's expedited approvals for promising treatments. Patient assistance programs and insurance coverage often influence customer purchasing behavior. Europe's melanoma drug market is highly regulated, with an emphasis on efficacious and cost-effective treatments. The European Union (EU) countries exhibit high consumer needs due to increasing melanoma cases and the presence of well-established healthcare systems. The adoption of new treatments is influenced by European Medicines Agency (EMA) regulations and HTA (Health Technology Assessment) bodies that assess the value of new medications. European Union initiatives supporting the ongoing research and development activities in melanoma drugs. Middle Eastern countries exhibit growing investment in healthcare and a rising need for innovative treatments. The Asia Pacific region is experiencing a surge in melanoma cases, with countries including China, Japan, and India contributing significantly to rising consumer needs. In APAC, increased investment in healthcare and innovation has begun to reshape the market. Melanoma drug market in APAC benefits from a combination of government initiatives and a strong pipeline of treatments in clinical trials.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Melanoma Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Melanoma Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int'l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Acral Lentiginous Melanoma
    • Lentigo Maligna Melanoma
    • Nodular Melanoma
    • Superficial Spreading Melanoma
  • Product
    • Adjuvant Therapy
    • Biochemotherapy
    • Chemotherapy Drugs
      • Dacarbazine (DTIC-Dome)
      • Temozolomide (Temodar)
    • Immunotherapy Drugs
      • Checkpoint Inhibitors
      • CTLA-4 Inhibitors
    • Oncolytic Virus Therapy
    • Targeted Therapy Drugs
      • BRAF Inhibitors
      • MEK Inhibitors
  • Distribution Channel
    • Offline
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Melanoma Drug Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Melanoma Drug Market?

3. What are the technology trends and regulatory frameworks in the Melanoma Drug Market?

4. What is the market share of the leading vendors in the Melanoma Drug Market?

5. Which modes and strategic moves are suitable for entering the Melanoma Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
      • 5.1.1.2. Increase in government expenditures on healthcare
      • 5.1.1.3. Elevated development of biosimilar in oncology arena
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
      • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies and lengthy approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
    • 5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
    • 5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Melanoma Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Acral Lentiginous Melanoma
  • 6.3. Lentigo Maligna Melanoma
  • 6.4. Nodular Melanoma
  • 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Product

  • 7.1. Introduction
  • 7.2. Adjuvant Therapy
  • 7.3. Biochemotherapy
  • 7.4. Chemotherapy Drugs
  • 7.5. Immunotherapy Drugs
  • 7.6. Oncolytic Virus Therapy
  • 7.7. Targeted Therapy Drugs

8. Melanoma Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Melanoma Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Melanoma Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Melanoma Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
    • 12.3.2. Sun Pharma and Philogen's Melanoma Drug Shows Promising Outcome in Phase 3 Trial
    • 12.3.3. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MELANOMA DRUG MARKET DYNAMICS
  • FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 170. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 174. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 184. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 185. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 188. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 189. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 192. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 193. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 200. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 201. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 202. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 203. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 204. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 205. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 206. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 207. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 210. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 211. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 212. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 213. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 214. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 215. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 216. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 217. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 220. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 221. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 226. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 227. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 228. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 229. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 230. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 231. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 234. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 235. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 240. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 241. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 242. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 243. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 244. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 245. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 246. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 247. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 248. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 249. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 254. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 256. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 258. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 262. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 263. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 268. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 269. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 270. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 271. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 272. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 273. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 276. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 277. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 280. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 281. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 284. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 286. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 290. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 291. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 294. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 295. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 296. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 297. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 300. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 301. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 304. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 305. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 310. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 311. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 312. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 313. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 314. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 315. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 316. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 317. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 318. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 319. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 322. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 323. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 324. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 325. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 326. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 327. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 328. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 329. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 330. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 331. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 332. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 339. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 340. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 341. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 344. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 345. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 346. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 347. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 349. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 354. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 355. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 356. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 357. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 358. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 359. DENMARK MELANOMA DR